Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Cummings, J; Zweifel, M; Smith, N; Ross, P; Peters, J; Rustin, G; Price, P; Middleton, M R; Ward, T; Dive, C (2012). Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. British journal of cancer, 106(11), pp. 1766-71. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.165

Full text not available from this repository.

OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Zweifel, Martin

ISSN:

0007-0920

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:36

Last Modified:

05 Dec 2022 14:11

Publisher DOI:

10.1038/bjc.2012.165

PubMed ID:

22538971

Web of Science ID:

000304353500009

URI:

https://boris.unibe.ch/id/eprint/14286 (FactScience: 221162)

Actions (login required)

Edit item Edit item
Provide Feedback